Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.755 USD | +3.61% | +15.87% | +30.75% |
May. 30 | GoodRx Holdings, Inc Announces Board and Committee Changes | CI |
May. 23 | RBC Upgrades GoodRx Holdings to Outperform From Sector Perform, Boosts Price Target to $10 From $8 | MT |
Evolution of the average Target Price on GoodRx Holdings, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering GoodRx Holdings, Inc.
RBC Capital Markets | |
Barclays | |
UBS | |
Deutsche Bank Securities | |
Raymond James | |
KeyBanc Capital Markets | |
Wells Fargo Securities | |
Goldman Sachs | |
TD Cowen | |
Truist Securities | |
JPMorgan Chase | |
Leerink Partners | |
BofA Securities | |
Morgan Stanley | |
Citigroup | |
Evercore ISI | |
Credit Suisse | |
DA Davidson | |
SVB Securities LLC | |
Guggenheim | |
Baird | |
Cowen | |
SVB Leerink | |
Stephens Inc. | |
Jefferies & Co. |
EPS Revisions
- Stock Market
- Equities
- GDRX Stock
- Consensus GoodRx Holdings, Inc.